AnaCardio raises €63M Series B for 'safer' heart failure drug
What's the deal? Swedish biotech AnaCardio has raised €63 million ($70.9 million) in a Series B round. The funding will help prepare its chronic advanced heart failure drug for registrational development.
What's the endgame? AnaCardio is developing a treatment for chronic advanced heart failure, positioning it as a safer option for patients. The new capital moves the drug toward the stage required for regulatory approval.
The signal: The round ranks among the larger Series B raises for Swedish health startups, landing in the top 10% of all such deals on record. That signals continued investor appetite for late-stage biotech tackling large, underserved conditions like heart failure.
Read more: endpoints.news
Image credit: AnaCardio
